GlassScriptPhysician profile
David S Tysinger
NPI 1538317698
$10,461.86
in general payments reported to CMS, 2019-2025
56 companies · $2,387 in 2025
The $2,387 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,940 · 2022: $1,927 · 2023: $1,946 · 2024: $2,263 · 2025: $2,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,527 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,526.80 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,445.16 | 2021-2025 | Biktarvy |
| Novo Nordisk INC | $909.98 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $840.13 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $760.11 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Viiv Healthcare Company | $726.14 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Abbvie INC. | $518.78 | 2021-2025 | |
| Amgen INC. | $515.15 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $501.75 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $321.54 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $312.46 | 2021-2025 | |
| Pfizer INC. | $309.20 | 2021-2025 | |
| Astellas Pharma US INC | $300.66 | 2021-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $231.98 | 2021-2025 | Spravato, Xarelto |
| Exact Sciences Corporation | $230.39 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.38 | 2021-2025 | Jardiance, Synjardy |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tysinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.